title: [PyNPase activity in primary and metastatic colorectal cancer].
abstract: 5'-Deoxy-5-fluorouridine (5'-DFUR) is converted to 5-FU by the enzyme of Pyrimidine nucleoside phosphorylase (PyNPase). Its efficacy for lung metastases from colorectal cancer is known. So we investigated PyNPase activity in primary and metastatic lesions of colorectal cancer patients. The results revealed that PyNPase activity (microgram 5-FU/mg protein/hour) (mean +/- SD) was 122.1 +/- 61.1 (n = 48) in primary lesions, 91.6 +/- 48.3 (n = 4) in lymph node metastases, 135.2 +/- 56.4 (n = 10) in liver metastases and 168.2 +/- 79.8 (n = 11) in lung metastases. In non-cancerous tissues adjacent to the cancer lesions, PyNPase activity was 51.5 +/- 18.8 in normal colorectal mucosa, 61.8 +/- 24.7 in normal liver and 43.0 +/- 21.2 in normal lung. These results demonstrated that PyNPase activity in the cancer lesions reached significantly higher levels than in the non-cancerous tissues (p < 0.01); and the T/N ratio of PyNPase activity in lung was also significantly higher than in primary or other metastatic lesions (p < 0.05). It was surmised that the clinical response of colorectal cancer to 5'-DFUR had been influenced by PyNPase activity.
authors.affiliation: Dept. of Surgery, Osaka Medical Center for Cancer and Cardiovascular Diseases.
authors.forename: M
authors.initials: M
authors.lastname: Kameyama
authors.forename: S
authors.initials: S
authors.lastname: Nakamori
authors.forename: S
authors.initials: S
authors.lastname: Imaoka
authors.forename: T
authors.initials: T
authors.lastname: Yasuda
authors.forename: H
authors.initials: H
authors.lastname: Ohigashi
authors.forename: M
authors.initials: M
authors.lastname: Hiratsuka
authors.forename: Y
authors.initials: Y
authors.lastname: Sasaki
authors.forename: T
authors.initials: T
authors.lastname: Kabuto
authors.forename: O
authors.initials: O
authors.lastname: Ishikawa
authors.forename: H
authors.initials: H
authors.lastname: Furukawa
authors.forename: T
authors.initials: T
authors.lastname: Iwanaga
authors.forename: H
authors.initials: H
authors.lastname: Yokouchi
authors.forename: O
authors.initials: O
authors.lastname: Doi
mesh_terms: D000230:Adenocarcinoma / Q000188:drug therapy / Q000201:enzymology* / Q000556:secondary*; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D015179:Colorectal Neoplasms / Q000188:drug therapy / Q000201:enzymology* / Q000473:pathology* / Q000556:secondary; D005260:Female; D005467:Floxuridine / Q000627:therapeutic use; D006801:Humans; D008113:Liver Neoplasms / Q000201:enzymology / Q000556:secondary; D008175:Lung Neoplasms / Q000201:enzymology / Q000473:pathology / Q000556:secondary; D008207:Lymphatic Metastasis; D008297:Male; D008875:Middle Aged; D010430:Pentosyltransferases / Q000378:metabolism*; D057845:Pyrimidine Phosphorylases
chemical_list: D005467:Floxuridine; D010430:Pentosyltransferases; D057845:Pyrimidine Phosphorylases; C025034:doxifluridine